Other (Income)/Deductions - Net (Footnotes) (Details) - USD ($) $ in Millions		3 Months Ended
		Apr. 02, 2017	Apr. 03, 2016
Loss Contingencies [Line Items]
Royalty revenue	[1]	$ 86	$ 187
Gain on sale of investments		54
Gain on sale of property		$ 48
Income from contract resolution			116
Hisun Pfizer Pharmaceuticals Co. Ltd [Member]
Loss Contingencies [Line Items]
Equity method investment, impairment			$ 81
Equity method investment, ownership percentage			49.00%
Laboratorio Teuto Brasilero [Member]
Loss Contingencies [Line Items]
Equity method investment, impairment			$ 50
Equity method investment, ownership percentage		40.00%	40.00%
Xtandi [Member]
Loss Contingencies [Line Items]
Royalty revenue		$ 35
Distribution Rights [Member]
Loss Contingencies [Line Items]
Gain on disposition of intangible assets		42	$ 16
Collaborative Arrangement, Co-promotion [Member] | Enbrel [Member]
Loss Contingencies [Line Items]
Decrease in royalty revenue		$ 117
Royalty period		36 months

[1] Royalty-related income decreased in the first quarter of 2017, primarily due to lower royalty income for Enbrel of $117 million, resulting from the expiration on October 31, 2016 of the 36-month royalty period under the collaboration agreement for Enbrel in the U.S. and Canada (the collaboration period under the agreement expired on October 31, 2013), partially offset by the addition of Xtandi royalty-related income of $35 million.